Related Experiment Video
Updated: Jul 9, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Drug therapy for atrial fibrillation
Simone Musco1, Emily L Conway, Peter R Kowey
1Division of Cardiovascular Diseases, Main Line Heart Center, 556 Medical Office, Building East, 100 Lancaster Avenue, Wynnewood, PA 19096, USA.
The Medical Clinics of North America
|December 7, 2007
Summary
Atrial fibrillation (AF) is a common heart rhythm disorder. Treatment strategies focus on rate control or rhythm maintenance, with new drugs under investigation for prevention and adjunctive therapy.
Area of Science:
- Cardiology
- Electrophysiology
- Pharmacology
Background:
- Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia.
- AF incidence is rising due to an aging global population.
- Therapeutic approaches are tailored to rate control versus rhythm control.
Purpose of the Study:
- To review current and emerging pharmacologic therapies for atrial fibrillation.
- To discuss treatment strategies based on therapeutic goals (rate vs. rhythm control).
- To highlight novel drug development for AF prevention and management.
Main Methods:
- Literature review of current clinical practices and ongoing trials.
- Analysis of pharmacologic agents targeting AF mechanisms.
- Synthesis of evidence for new antiarrhythmic and anti-remodeling drugs.
Main Results:
- Treatment choice hinges on maintaining sinus rhythm or controlling ventricular rate.
- Novel antiarrhythmic drugs are under active clinical investigation.
- Agents targeting inflammation and remodeling show promise for AF prevention and adjunctive therapy.
Conclusions:
- Pharmacologic management of AF requires individualized strategies.
- Emerging therapies offer potential advancements in AF treatment and prevention.
- Further research is crucial to optimize the use of new drugs in AF management.
Related Concept Videos
01:25Dysrhythmias VI: Management of Dysrhythmias
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:25ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...